A Look At Doximity (DOCS) Valuation After Earnings Beat But Cautious Guidance

Doximity (DOCS) has been back in focus after its latest earnings, where revenue topped expectations, but guidance for the next quarter fell short, prompting a sharp market reaction and renewed questions about its growth trajectory.

See our latest analysis for Doximity.

That cautious guidance has been a key driver of recent weakness, with a 1 day share price return of 2.84% decline adding to a 30 day share price return of 14.24% decline and a 1 year total shareholder return of 60.68% decline. This points to fading momentum as investors reassess growth and risk around the US$21.86 level.

If you see merit in Doximity's healthcare AI tools and want to broaden your radar, now could be a useful moment to review 34 healthcare AI stocks.

With Doximity now trading around US$21.86, a reported intrinsic discount of about 56% and a forward P/E below peers, the key question is whether this reflects undervaluation or whether the market is already pricing in future growth.

Most Popular Narrative: 44.7% Undervalued

With Doximity closing at about $21.86 against a narrative fair value of roughly $39.55, the current gap hinges on how durable its healthcare platform really is.

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time, supporting long-term revenue and margin expansion.

Read the complete narrative.

Curious what kind of revenue path and profit margins are baked into that fair value, and what future P/E multiple it assumes for a healthcare software name? The narrative leans on steady top line growth, durable profitability and a richer earnings multiple than today to bridge the gap between $21.86 and $39.55, with analyst assumptions doing most of the heavy lifting behind the scenes.

Result: Fair Value of $39.55 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside story runs into real hurdles if free AI tools prove slow to monetize, or if pharma marketing budgets or regulations tighten and hit Doximity’s core revenue stream.

Find out about the key risks to this Doximity narrative.

Next Steps

With sentiment clearly split between opportunity and risk, it makes sense to move quickly and ground your own view in the underlying facts, starting with the 4 key rewards.

Looking for more investment ideas?

If Doximity is on your radar, do not stop there. The next strong idea often comes from looking one step beyond your current watchlist.

• Target dependable income by reviewing 12 dividend fortresses that focus on higher yielding opportunities with an emphasis on stability.
• Hunt for quality at a discount by checking out 64 high quality undervalued stocks that combine solid fundamentals with pricing that may look appealing.
• Prioritize resilience by scanning 72 resilient stocks with low risk scores that score well on financial strength and business stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com